2026 Dyslipidemia Guidelines with Vera Bittner, MD, MSPH, FACC - Professor of Medicine, UAB

• Discuss how to risk stratify individuals with dyslipidemia.
• Rationalize the new PREVENT equations, interpret results from the PREVENT calculator, and when not to use the PREVENT calculator. 
• Design lipid lowering therapy to achieve treatment goals.

Imaging of soft and Vulnerable Plaque- Can We Predict ACS? - Tushar Mishra, MD

• Identify the morphological characteristics of vulnerable plaques.
• Evaluate the role of multimodal imaging. 
• Appraise current clinical trial evidence and future directions.

Panel session: Cardiogenic Shock - Heriberto Matos-Santana, MD; Gautam Reddy, MD; Akshay Khandelwal, MD MBA FACC FSCAI

• Identify early recognitions into the spiral of cardiogenic shock.
• Recognize the patient profiles that benefit from hemodynamic support. 
• Discuss the importance of palliative care consultation for shock patients. 
• Review a team-based approach to acute MI cardiogenic shock 
• Describe the prognosis of acute MI cardiogenic shock in various populations/presentations.

Lunch Program: Panel Session: Cardiac Resynchronization Therapy - Ruchit Shah, MD, FACC, FHRS; Michael Kaufmann, MD

• Describe the physiologic basis of conduction system pacing and how it differs from traditional right ventricular pacing and cardiac resynchronization therapy. 
• Describe key features of His bundle pacing vs. left bundle branch area pacing, including basic ECG characteristics. 
• Summarize current clinical evidence and ongoing clinical trials and understand where conduction system pacing fits relative to cardiac resynchronization therapy.

Management of POTS and Neurocardiogenic Syncope - Italo Biaggioni, MD

Panel Session: Cardiogenomics - Pankaj Arora, MD, FAHA, FASE; Catherine Smith, MS, CGC

• Recognize key genetic contributors to inherited and complex cardiovascular diseases. 
• Interpret genetic testing results, including polygenic risk scores, for clinical decision-making. 
• Implement personalized management strategies based on genomic risk in cardiovascular patients.

Update in Recent Clinical Trials - Brittain Heindl, MD

• Review key cardiovascular clinical trials from the past year and summarize their implications for contemporary clinical practice. 
• Evaluate evolving anticoagulation strategies across clinical settings, including atrial fibrillation and venous thromboembolism, with attention to optimization and de-escalation of combined antithrombotic therapy in patients with coexisting coronary artery disease. 
• Discuss lipid-lowering strategies, including emerging LDL targets in high-risk patients with and without established atherosclerotic cardiovascular disease.

Commercial Support
There is no commercial support for this activity.